pp-201 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
India
GMP approvals
India
Comments
Indication: Major depressive disorder (MDD)
Clinical stage: Phase 2b — ongoing
Modality: Small molecule (first-in-class nAChR antagonist)
Mechanism / Target: First-in-class selective α4β2 nicotinic acetylcholine receptor (nAChR) antagonist; modulates cholinergic neurotransmission in limbic circuits to produce antidepressant effects via a mechanism entirely distinct from monoamine reuptake inhibition
Route / form: Oral tablet
Differentiation: First-in-class nAChR antagonist for MDD; wholly novel cholinergic mechanism independent of serotonin/norepinephrine reuptake or receptor blockade; addresses patients with inadequate response to standard antidepressants;
Manufacturer #39338
India-based clinical-stage biopharmaceutical company with decades of expertise in CNS and neurodegenerative drug discovery. Develops proprietary Rx new chemical entities and provides drug-discovery services to global pharma and biotech companies. Listed on a domestic exchange.
None